General Updates

June 27, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, (E), MUMBAI -400 001 MUMBAI -400 051 Company Code No. 524804 Company Code No. AUROPHARMA Dear Sir / Madam, Sub: Completion of US FDA Inspection at Auroactive Pharma Private Limited, a wholly owned subsidiary of the Company – Reg., Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that: The United States Food and Drug Administration (US FDA) conducted an inspection at Auroactive Pharma Private Limited (a wholly owned subsidiary of the Company), which manufactures Active Pharmaceutical Ingredients (API) & Pharmaceutical Formulation Intermediates, situated at Sy Nos 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam District, 523 409, Andhra Pradesh, from June 22, 2026, to June 26, 2026. The inspection concluded with 2 observations and will be responded to within the stipulated time. The Company is committed to maintaining the highest quality manufacturing standards. We will keep the stock exchanges informed if there is any further information relating to the above in the future. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as ‘Annexure’. Please take the above information on record. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Encl: Annexure Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com Annexure Sr. No. Particulars Details 1 Name of the authority US Food and Drug Administration (US FDA), USA 2 Nature and details of the action(s) taken, The United States Food and Drug Administration initiated or order(s) passed by the Authority (US FDA) conducted an inspection at Auroactive Pharma Private Limited (a wholly owned subsidiary of the Company), which manufactures Active Pharmaceutical Ingredients (API) & Pharmaceutical Formulation Intermediates, situated at Sy Nos 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam District, 523 409, Andhra Pradesh, from June 22, 2026, to June 26, 2026. 3 Date of receipt of direction or order, including June 26, 2026. any ad-interim or interim orders, or any other communication from the authority 4 Details of the violation(s)/ contravention(s) The inspection concluded with 2 observations committed or alleged to be committed and will be responded to within the stipulated time. 5 Impact on financial, operation, or other There is no impact on the Company’s financials activities of the listed entity, quantifiable in or operations due to the said action. monetary terms to the extent possible Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com